1. Home
  2. GCBC vs CBIO Comparison

GCBC vs CBIO Comparison

Compare GCBC & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Greene County Bancorp Inc.

GCBC

Greene County Bancorp Inc.

HOLD

Current Price

$22.30

Market Cap

374.8M

Sector

Finance

ML Signal

HOLD

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$11.96

Market Cap

389.7M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
GCBC
CBIO
Founded
1889
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Banks
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
374.8M
389.7M
IPO Year
1998
N/A

Fundamental Metrics

Financial Performance
Metric
GCBC
CBIO
Price
$22.30
$11.96
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$26.67
AVG Volume (30 Days)
8.6K
181.9K
Earning Date
04-22-2026
01-01-0001
Dividend Yield
1.80%
N/A
EPS Growth
26.21
N/A
EPS
1.13
N/A
Revenue
$4,117,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.66
N/A
Revenue Growth
11.06
N/A
52 Week Low
$20.00
$8.72
52 Week High
$26.21
$17.39

Technical Indicators

Market Signals
Indicator
GCBC
CBIO
Relative Strength Index (RSI) 43.63 57.59
Support Level $21.39 $11.88
Resistance Level $23.48 $13.37
Average True Range (ATR) 0.83 1.01
MACD -0.10 0.12
Stochastic Oscillator 19.70 68.65

Price Performance

Historical Comparison
GCBC
CBIO

About GCBC Greene County Bancorp Inc.

Greene County Bancorp Inc is a holding firm. Its primary business involves overseeing and directing the business of The Bank of Greene County and monitoring its cash position. Through its directly and indirectly owned subsidiaries, the company engages in attracting retail deposits, along with funds generated from operations and borrowings, predominantly in one to four-family residential mortgage loans, commercial real estate mortgage loans, consumer loans, home equity loans, and commercial business loans. It also serves local municipalities' banking needs and operates a real estate investment trust.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: